Journal article

No Increase in Hepatitis B Virus (HBV)-Specific CD8( ) T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy

Megan Crane, Sunee Sirivichayakul, J Judy Chang, Anchalee Avihingsanon, Sasiwimol Ubolyam, Supranee Buranapraditkun, Pattarawat Thantiworasit, Fiona Wightman, Stephen Locarnini, Gail Matthews, Gregory J Dore, Kiat Ruxrungtham, Sharon R Lewin

Journal of Virology | AMER SOC MICROBIOLOGY | Published : 2010

Abstract

Following treatment of hepatitis B virus (HBV) monoinfection, HBV-specific T-cell responses increase significantly; however, little is known about the recovery of HBV-specific T-cell responses following HBV-active highly active antiretroviral therapy (HAART) in HIV-HBV coinfected patients. HIV-HBV coinfected patients who were treatment naïve and initiating HBV-active HAART were recruited as part of a prospective cohort study in Thailand and followed for 48 weeks (n = 24). Production of gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) in both HBV- and HIV-specific CD8(+) T cells was quantified using intracellular cytokine staining on whole blood. Following HBV-active H..

View full abstract

Grants

Awarded by National Institutes of Health


Awarded by National Health and Medicine Research Council


Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Funding Acknowledgements

This study was funded by the National Institutes of Health (NIH R21 AI055379-01) and Gilead Sciences. S. R. L. is supported by the Alfred Foundation and is a National Health and Medicine Research Council Practitioner Fellow (grant 251651).K. R. has recently received research grants/funding, honoraria, or has been a consultant or advisor to, or received lecture sponsorships from Abbott, Boehringer-Ingelheim, Bristol-Myers-Squibb, Gilead, GlaxoSmithKline, Hoffmann-LaRoche, Janssen-Cilag, Merck Sharpe & Dolme, Tibotec and Virco. S. R. L. has received research grants/funding from Roche, Bristol-Myers-Squibb, Gilead, and Pfizer.We thank Tim Spelman for his expert statistical advice, Pip Marks for study coordination, and the patients for their participation in this study.